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ChondrosarcomaThe skeleton is subject to dynamic changes throughout life and bone remodeling is essential for maintenance of
bone functionality. The cell populations which predominantly participate in bone and cartilage remodeling,
namely osteocytes, osteoblasts, osteoclasts and chondrocytes sense and respond to external mechanical signals
and via a series of molecular cascades control bone metabolism and turnover rate. The aforementioned process,
known as mechanotransduction, is the underlying mechanism that controls bone homeostasis and function. A
wide array of cross-talking signaling pathways has been found to play an important role in the preservation of
bone and cartilage tissue health. Moreover, alterations in bone mechanotransduction pathways, due to genetic,
hormonal and biomechanical factors, are considered responsible for the pathogenesis of bone and cartilage
diseases. Extensive research has been conducted and demonstrated that aberrations in mechanotransduction
pathways result in disease-like effects, however only few signaling pathways have actually been engaged in
the development of bone disease. The aim of the present review is to present these signaling molecules and
cascades that have been found to be mechano-responsive and implicated in bone disease development, as
revealed by research in the last ﬁve years. In addition, the role of these molecules as prognostic or diagnostic
disease markers and their potential as therapeutic targets are also discussed.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Bone comprises a continuously regenerated tissue, a process achieved
through consecutive bone resorption and synthesis cycles. This complex
procedure, called bone remodeling, involves a tightly controlled process
while alterations at various steps result in bone disease initiation [1].
Bone remodeling is largely subject to environmental mechanical
cues [2–4]. For example, it has been shown that bone tissue goes through
atrophy in older people as a result of decreased levels of physical exercise
and stationary life style as well as in younger people experiencing
microgravity conditions [5]. Bone and cartilage cells have the ability
to sense mechanical signals and alter their responses accordingly.
This is accomplished through mechanotransduction pathways that
result in altered bone remodeling according to the nature of the
mechanical signals received. More speciﬁcally, it has been observed
that continuous repetitive application of mechanical signals that
cause high strain or uneven load distribution leads to increased
bone synthesis. Moreover, short pauses between long periods of
mechanical force application have been demonstrated to be beneﬁcial
for bone strength and structure [6]. On the other hand, static load as
well as “predictable” mechanical signal application bear the opposite
effects of reduced bone synthesis and increased bone resorption [7].emistry, Cellular andMolecular
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l.com (E.K. Basdra).Bone homeostasis and function can be deregulated through several
conditions affecting bone and cartilage biology. The most common of
them is osteoporosis, where decreased bone mass is a result of hormonal
status or disuse. In addition, Paget's disease, osteogenesis imperfecta,
osteopetrosis and osteosarcoma are among other frequent disorders
where bone architecture is affected. Bone health can also be affected by
changes in cartilage biology. Osteoarthritis (OA) comprises a condition
affecting not only cartilage but also bone tissue. Other conditions affecting
the cartilage are achondroplasia, costochondritis, spinal disk herniation,
relapsing polychondritis, chondromas and chondrosarcomas.
Several of the aforementioned diseases could possibly be the result
of altered bone remodeling. Altered remodeling process can be the
result of normal adaptation to changedmechanical signals or pathological
factors like distorted mechano-responsiveness of osteocyte, osteoblast,
osteoclast or chondrocyte cells, deregulated mechanotransduction
pathways or altered bone matrix mechanical properties. All of the
above, or a combination of those factors could lead to pathological
bone remodeling and thus disease development [8].
Altered mechanotransduction signaling cascades have been shown
to result in deregulated bone remodeling and disease-like effects [9].
However, the speciﬁc deregulated signaling pathways implicated in
bone disease have not been yet extensively studied. This review
will focus on what is known on mechanotransduction molecular
mechanisms involved in bone disease development, as well as the
potential of some of the engaged molecules as prognostic or diagnostic
markers and their perspective in developing new therapeutic strategies
against bone disease.
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Osteoarthritis (OA), themost frequently observeddegenerative joint
disease, is characterized by a progressive degeneration of articular
cartilage which also largely affects synovial membrane and subchondral
bone [10]. Although its etiology remains unclear, genetic factors, obesity,
diabetes, metabolic syndrome, hypertension, hyperuricemia, muscle
weakness, underlying anatomical and orthopedic disorders, joint
infection, crystal deposition, previous rheumatoid arthritis (RA),
various disorders of bone turnover and blood clotting, hypermobility,
previous trauma to the joint causing inﬂammation, aging and biomechan-
ical stress, have all been suggested as responsible for disease initiation
[10–13]. Production of interleukin 1 beta (IL-1β) and tumor necrosis fac-
tor alpha (TNFα) pro-inﬂammatory cytokines by cartilage chondrocytes
comprises common characteristics of the disease [14].
In recent years, evidence that mechanical factors play important
roles in its pathology has been accumulated as reviewed by Brandt
et al. [14]. More speciﬁcally, direct or indirect injuries and elevated
mechanical strain caused by factors like obesity, joint malalignment,
chondrodysplasias and abnormal gait, have been shown to result in
OA development [15]. In addition, research has shown that pro-
inﬂammatory molecule activity in coordination with alterations in
mechanical environment seems to be of major importance in the
development of the disease [16].
For example, mechanical stimulation of highmagnitude is known to
result in tissue injury and release of cartilage matrix degradation
products. These molecules, in turn, induce inﬂammatory pathways
and thus lead to OA development. Furthermore, altered mechanical
in combination with oxidative stimuli in osteoarthritic joints are
considered to be implicated in inﬂammation initiation through the
release of molecules like cytokines, chemokines, cyclooxygenase
(COX)-2, microsomal PGE synthase-1 (mPGES-1), soluble phospholipase
A2 (sPLA2), and inducible nitric oxide synthase (NOS2) [17]. Those
released molecules are not only characteristic of the disease but some of
them may be potential disease markers or therapeutic targets. For
example, synovial ﬂuid IL-1β and IL-18 were demonstrated to be
linked with OA severity and IL-18 with OA progression [18]. C–C
motif chemokine 19 (CCL19) and C–C chemokine receptor type 7
(CCR7) expression has been associated with increased OA severity
in patients at early OA stage [19]. Additionally, increased CCL5 and
CCL19 levels have been detected in synovial ﬂuids of OA and RA
patients and could serve as diagnostic markers in the future [20].
Furthermore, CCL2 and IL-8were among biomarkers thatwere expressed
at different levels in osteoarthritic and non-pathological animal models
and may act as potential diagnostic markers [21]. Serum IL-15 may
comprise an early prognostic marker since its expression may be
indicative of a more severe disease progression [22]. Inhibitors or
antagonists for some of those molecules, like nitric oxide synthase
(NOS) or IL-1 receptor, may have effects in reducing OA severity, as
suggested by in vivo studies [23,24].
Furthermore, another recent study in patients with knee OA revealed
that treatment with a dual inhibitor of 5-lipoxygenase and COX resulted
in a substantial reduction of serum matrix metalloproteinase (MMP)-1
and MMP-3 levels, accompanied with decreased cartilage loss, thus
revealing COX as a potent therapeutic OA target [25].
Osteoclast-derived transforming growth factor beta 1 (TGF-β1) seems
to also be implicated in OA initiation due to distorted mechanical signals.
More speciﬁcally, TGF-β1 was found to be elevated in subchondral bone
following application of altered mechanical stimuli in a speciﬁc mouse
model of OA. Increased TGF-β1 levels have also been observed in the
same tissue in patients suffering from the disease. In addition, the same
research group found that transgenic expression of the molecule in non-
pathological osteoblastic cells led to OA development, while its inhibition
in subchondral bone tissue prevented articular cartilage degeneration
[26]. Transforming growth factor β receptor type I (TGFβRI) kinase
and phospho-Smad2/3 pathways seem to also be activated throughmechanical shear stress and to regulate superﬁcial zone protein (SZP)
expression patterns. SZP is a mucinous glycoprotein secreted by tissues
adjacent to the interior of joint surfaces. These glycoproteins are respon-
sible for the protection of the joints against direct solid-to-solid contact
[27], while their decreased levels have been associated with OA develop-
ment [28,29]. SZP expression is characterizedbypatterns of localization as
it has been shown in bovine cartilage. More speciﬁcally, elevated SZP
expression is observed in load-bearing regions [28–30].
Conclusively, inﬂammatory and mechanical signals are intimately
correlated with OA development, creating positive feedback loops and
further promoting disease progression, while the initiator molecules
remain elusive.
Cartilage matrix degrading enzymes which are responsible for matrix
degradation seem to be of major importance in the development of the
disease. The most common degrading enzymes in osteoarthritic joints
are the collagenases MMP-1, MMP-13 and MMP-3, the aggrecanases
A disintegrin and metalloproteinase with thrombospondin motifs
(ADAMTS)-4 and ADAMTS-5 as well as several serine and cysteine
proteases like cathepsins K [31]. This group of cartilage matrix
degrading enzymes seems to be responsive to mechanical signals [32].
For example, mechanical stimuli have been shown to result in the activa-
tion of high temperature requirement A1 (HTRA1), a serine protease, and
thus to matrix degradation [33]. Following HTRA1 activation, discoidin
domain receptor 2 (DDR2) tyrosine kinase binds to its ligand, native
type II collagen, becomes activated and activates MMP-13 resulting in
further matrix degradation [34].
Some of the above molecules could serve as diagnostic markers in
the future. More speciﬁcally, MMP-3 has been found to be a sensitive
marker for early OA alterations [35], while its serum levels have been
shown to be associated with histopathological ﬁndings in knee joints
of osteoarthritic animal models [36]. MMP-2 and tissue inhibitor of
MMP (TIMP)-2 levels in synovial ﬂuids may be indicative of early
phase OA as suggested in canines [37]. Furthermore, MMP-2 and
MMP-3were among biomarkers that were expressed at different levels
in disease in a study using osteoarthritic and non-osteoarthritic animal
models [21]. These ﬁndings implicate MMPs as diagnostic markers for
early stage OA. Moreover, a number of assays have been established in
order to locate neoepitopes of cleavaged aggrecan and thus aggrecanase
activity in biological ﬂuids [38–40]. Although there is not much evidence
up until now, these assays detected aggrecanase activity in urine of OA
patients [40]. Some products of matrix cartilage degradation have the
ability to activate innate immune responses. For example, oligomeric
matrix protein (COMP) bears the capacity to activate the alternative
complement pathway while complexes of COMP and C3b have been
found in synovial ﬂuids of patients with OA [41]. Additionally, other
studies have demonstrated increased COMP levels in patients with the
disease [42–44]. Since COMP comprises a mechano-sensitive molecule
[45], some researchers have proposed to employ mechanical stimuli,
like exercise, in order to elevate its sensitivity as a prognostic marker
of a healthy or osteoarthritic cartilage [46,47].
A number of thesemolecules could also have a therapeutic potential.
For example, results from a study using a potent inhibitor ofMMPs, BAY
12-9566, on patients with OA, indicated that aggrecan synthesis levels
might have been enhanced [48]. Another inhibitor for MMP-13, PF152,
was tested on surgically-induced dog osteoarthritic cartilage explants
and resulted in decreased cartilage lesions as well as noticeable reduction
of aggrecanase-speciﬁc markers [49]. An ADAMTS-4/5 inhibitor, AGG-
523, succeeded in reducing synovial ﬂuid aggrecanase in a model of
surgically-induced joint instability [50]. In addition, lack of ADAMTS5
activity has been shown to decrease osteoarthritic cartilage decomposi-
tion in a murine model of surgically induced OA, further highlighting
the potent role of the molecule as a therapeutic target [51].
The primary cilium comprises a mechanotransduction organelle
projecting into the extracellular environment [52]. Studies have
shown that chondrocyte primary cilia are not only involved in
mechanotransduction but also participate in inﬂammatory cytokine
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hedgehog signaling [54,55]. For example, in osteoarthritic cartilage, cilia
length has been observed to be increased [56] and hedgehog signaling
molecules display elevated expression [55]. Furthermore, primary cilium
has been demonstrated to mediate IL-1 inﬂammatory response in
primary chondrocytes and human ﬁbroblasts. More speciﬁcally, in the
case of primary chondrocytes, IL-1 treatment resulted in increased cilia
length through a protein kinase A (PKA)-dependent mechanism. In
addition, IL-1 treatment resulted in elevated inﬂammatory chemokine,
nitric oxide (NO) and prostaglandin E2 (PGE2) expression [53].
Moreover, although primary cilia are expressed in chondrocytes of OA
patients [57,58], their orientation seems to differ. Primary cilia of non-
pathological articular chondrocytes are characterized by a speciﬁc
orientation, projecting away from the articular surface, whereas those
fromosteoarthritic chondrocytes are characterized by an altered orienta-
tion, projecting to the center of the articular surface [56]. Research on
Col2aCre;ift88(ﬂ/ﬂ) transgenic mice demonstrated that chondrocytes
lacking primary cilia express elevated levels of OA markers like MMP-
13, ADAMTS-5, type X collagen (COLX) and Runt-related transcription
factor 2 (RUNX2) [59], while having thicker cartilage with reduced me-
chanical responsiveness [60]. Because primary cilia are also expressed
in chondrogenic progenitor cells that confer the ability to differentiate
towards chondrocytes and thus promote new cartilage development,
in addition to their role in inﬂammatory responses, they could be a
promising therapeutic target against OA [61].
Hedgehog (Hh) signaling is found to be active in osteoarthritic
human samples as well as mouse models mimicking the disease. It has
also been observed that the more increased the levels of Hh signaling
in chondrocytes are, the more severe the osteoarthritic phenotype,
while Hh signaling inhibition decreases disease effects. Runx2 transcrip-
tion factor is probably involved in the aforementioned pathway since it
seems to control disintegrin and ADAMTS-5 expression [55]. Along with
Hh signaling, another molecule, Sox9 transcription factor, is known to
play crucial roles in chondrocyte differentiation [62]. Sox9 is a master
regulator of downstream molecules like collagen type II and aggrecan,
necessary for cartilage development [62]. Research has shown that Sox9
expression is decreased in osteoarthritic chondrocytes as compared to
non-pathological ones [63]. Fromall the above observations, a therapeutic
potential in targeting the primary cilium and Hh signaling pathways is
evident in order to prevent OA development.
Other OA animal models studying molecular pathways involved in
disease pathology have shown that nuclear factor kappa B (NF-κB) tran-
scription factor activation [64], as well as mechanoreceptor activation
by mechanical signals induce mitogen activated protein kinase (MAPK)
cascades [65] which regulate the expression of downstream molecules
like MMP-13, NOS2, COX2, ADAMTS and IL-1β [66]. Furthermore, MAPK
signaling and more speciﬁcally extracellular-regulated kinase (ERK),
c-Jun N-terminal kinase (JNK) and p38 MAPK signaling pathways pro-
mote the expression/activation of transcription factors such as activator
protein 1 (AP-1), E26 transformation-speciﬁc (ETS), Runx2, hypoxia-
inducible factor 2 alpha (HIF-2α) and CCAAT-enhancer-binding protein
beta (C/EBPβ), which together with NF-κB result again in catabolic and
inﬂammatory response initiation [67–72]. A pro-apoptotic molecule of
the Bcl-2 family, p53 upregulated modulator of apoptosis (PUMA), is
found to be up-regulated and to induce apoptosis in chondrocytes
following IL-1β treatment. This observed increased expression
seems to also be regulated through JNK/c-Jun pathway. In addition,
elevated levels of PUMA and c-Jun have been found in articular cartilage
chondrocytes of OA patients, suggesting a role for the molecules in
chondrocyte apoptosis in osteoarthritic cartilage [73].
Janus kinase (JAK)-signal transducer and activator of transcription
(STAT) signaling pathway have emerged as a very important cascade
in bone development and metabolism [74]. This pathway not only
plays a signiﬁcant role in bone biology but it has also been shown to
be involved in transducing mechanical signals [75] and thus research
has focused on studying its implication, if any, in OA. Suppressor ofcytokine signaling (SOCS) proteins, inhibitors of the JAK/STAT pathway,
has also been reported to be of importance in bone biology [76–78],
while they have also been recently shown to be involved in molecular
pathways of OA. More speciﬁcally, SOCS2 and cytokine-inducible SH2-
domain-1 (CIS-1) mRNA levels were decreased by 10-fold in OA
chondrocytes compared to controls. In addition, reduced SOCS2 and
CIS-1 mRNA levels were observed following normal chondrocyte
treatment with inﬂammatory cytokines IL-1β and oncostatin-M
(OSM) in the presence of TNFα for a long period of time [79].
Elevated reactive oxygen species (ROS) production due tomechanical
strain, cytokine release or matrix fragments may promote cell death in
osteoarthritic tissues [66]. Caspase inhibitors, which prevent cells from
following apoptotic pathways, have been shown to exert protective
roles against OAby reducing its severity in a rabbitmodel [80]. Autophagy
on the other hand, which protects cells under stress by leading them to
death, decreases more as the disease progresses [81]. Rapamycin inhibi-
tion of the mammalian target of rapamycin (mTOR) signaling pathway
has been observed to activate autophagy and decrease OA severity in
murine models [82]. These observations indicate potent therapeutic
strategies against OA, either by using apoptosis inhibitors or by
employing mechanisms to enhance autophagy activation.
The presence of mechanoresponsive miRNAs, as well as the existence
of miRNAs that may bear the ability to regulate mechanotransduction,
have been demonstrated in chondrocytes [83]. miR-146a has been
observed to be induced by joint instability due to medial collateral
ligament transection and medial meniscal tear in the knee joints of
an OA mouse model, leading to the hypothesis that it may regulate
mechanotransduction pathways in articular cartilage [84]. The same
miRNA is also highly expressed in peripheral blood mononuclear cells
(PBMCs) of OA patients [85], while its expression levels have been
found elevated in early-stage OA patients. Interestingly, its expression
decreases when the disease has progressed, an observation that
implicates miR-146a as a potent early disease diagnosis marker [86].
Speciﬁc physiological responses to mechanical signals seem to be
absent in osteoarthritic chondrocytes, indicating that altered signaling
takes place in OA development [87]. For example, mechanical stimuli
that are transmitted through the a5b1 integrin and result in augmented
aggrecan and decreased MMP-3 expression levels have not been
documented in chondrocytes derived from pathological cartilage
tissues [88].
Research efforts continue in order to identify new molecules and
pathways implicated in OA. Recently, gene expression proﬁling
in cartilage isolated from a surgically-induced OA mouse model
conﬁrmed OA-related genes, like prostaglandin-endoperoxide synthase 2
(Ptgs2), cytokine receptor-like factor 1 (Crlf1) as well as inhibin beta A
(Inhba), and revealed previously unidentiﬁed in OA genes such as
pleckstrin homology-like domain family A member 2 (Phlda2) and interleu-
kin 11 (Il11), which all exert their effects independently of ADAMTS-5
activity. On the other hand, another group of genes was found to be
implicated in disease but to require ADAMTS-5 activity. Among those
genes were Col10a1 and Wnt/β-catenin pathway genes. Furthermore,
cell death-related gene expression was found altered, tumor suppressor
p53, forkhead box O4 (Foxo4) and X-box binding protein 1 (Xbp1)
endoplasmic reticulum stress molecular pathways were found activated
and matrix metallopeptidase 3 (Mmp3), calpain 2 (Capn2), protease
serine 46 (Prss46) and kallikrein-related peptidase 8 (Klk8) protease
gene expression was found increased [89] (Fig. 1).3. Spondyloarthritides
Spondyloarthritides (SpA) comprise chronic disorders characterized
by asymmetrical peripheral arthritis, mainly of the lower limbs, as well
as axial inﬂammation.Other SpA characteristics are enthesitis, which in-
volves inﬂammation on attachment sites of ligaments [90] and new bone
synthesis advancing towards ankylosis or enthesophyte development
Fig. 1. Altered mechanotransduction signaling implicated in osteoarthritis. Deregulated mechanotransduction in co-ordination with inﬂammatory processes results in altered signaling
cascades. These responses, in turn, promote osteoarthritis development. Deregulatedmechano-responsive signaling pathways in osteoarthritis are depicted. TGF-β1, transforming growth
factor beta 1; SZP, superﬁcial zone protein; TGFβRI, transforming growth factor β receptor type I; Hh, hedgehog; NF-κB, nuclear factor kappa B; MAPK, mitogen activated protein kinase;
SOCS2, suppressor of cytokine signaling; CIS-1, cytokine-inducible SH2-domain-1; ROS, reactive oxygen species; mTOR, mechanistic target of rapamycin.
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following RA [92].
Recent studies have provided strong evidence thatmechanical strain
results in entheseal inﬂammation as well as new bone synthesis in SpA.
ERK1/2 signalingwas shown to be involved in normal as well as disease
mechanotransduction pathways in Achilles tendon. In this regard,
Jacques et al. [93] evaluated the effects of an ERK1/2 inhibitor and a
p38 inhibitor on enthesitis development. The results were promising
with the PD98059 ERK1/2 inhibitor reducing inﬂammation within the
synovio-entheseal complex and leading to decreased levels of calcaneal
bone erosion [93].
4. Osteosarcoma
Osteosarcoma (OS) is the most common primary malignant bone
tumor. It is quite aggressive and often metastasizes to the lungs [94].
OS originates from transformed mesenchymal cells differentiating and
forming osteoid and bone tissues [95]. OS is more commonly observed
in the metaphysis of long bones and around the knee area [94].
Osteosarcoma studies have focused on focal adhesions and the
pathways activated following mechanical stimulation of osteosarcoma
cells. These studies have shown that mechanical stimulation results in
two different responses in osteosarcoma cells. More speciﬁcally,
seconds of mechanical stimulus application resulted in rapid growth
of focal adhesions, an effect promoted by focal adhesion kinase (FAK)
and inhibited by proto-oncogene tyrosine–protein kinase Src (Src). On
the other hand, several minutes of mechanical stimulation resulted in
focal adhesion disassembly only in cells that bear long axes perpendicularto mechanical force application, a response regulated by FAK, Src and
calpain 2 [96].
Tenascin-C (TN-C) is a mechanosensitive extracellular matrix
molecule that has been implicated in tumor development. Studies
on osteosarcoma cells following mechanical application have
conﬁrmed its involvement in osteosarcoma development and have
demonstrated that mechanical signals alone as well as mechanical
signals in combination with pro-epidermal growth factor (EGF)
and insulin-like growth factor I (IGF-1) treatment result in TN-C
increased expression. Rho-associated protein kinase (ROCK)-I/II
and dual speciﬁcity mitogen-activated protein kinase kinase 1 (MEK-1)
were implicated in TN-C elevated expression after growth factor treat-
ment, whereas only ROCK-I/II was involved in mechanical stimulation
effects [97]. TN-C FNIIIA1 variant expression has also been found to be
elevated in tumors, an observation also conﬁrmed in osteosarcomas
[98]. The same research team showed that TN-C FNIIIA1 is implicated
in osteosarcoma cell migration and that mechanical stimulation caused
TN-C FNIIIA1 increased expression levels through mTOR signaling, an
effect that further enhanced osteosarcoma cell migration [98]. These
ﬁndings suggest that TN-C FNIIIA1 could potentially prove a molecule
for therapeutic targeting of metastatic osteosarcomas as well as a potent
marker for cancer cell migration in patients with osteosarcoma.
5. Chondrosarcoma
Chondrosarcoma is a malignant tumor formed by transformed
chondrocytes that mainly affects the bone and cartilage. Chondro-
sarcomas grow at slow rates and rarely metastasize [99].
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chondrosarcoma pathobiology. More speciﬁcally, it has been shown
that primary cilia are present at lower frequencies in transformed
chondrocytes than in non-pathological ones (about 50%). Furthermore,
it was demonstrated that primary cilia inhibit Hh signaling in
transformed chondrocytes, hence preventing tumor development
and bearing a protective role against chondrosarcoma initiation [100].
Thus, this research indicates the implication of other molecular mecha-
nisms in chondrosarcoma development, mechanisms that are capable
to counteract the protective effects conferred by mechanotransduction
through primary cilia (Fig. 2).6. Degenerative disk disease
Degenerative disk disease (DDD) is a disorder causing degeneration
of intervertebral disk (IVD)matrix. The IVD, with its gelatinous nucleus
pulposus (NP) and peripheral collagenous annulus ﬁbrosus (AF),
comprises a structure that confers stability and ﬂexibility to the
spine. This structure is sensitive to mechanical stimulation and
application of irregularmechanical signals results inmatrix degradation
[101,102]. DDD initiates in NP and as the disease progresses it affects
other disk components [103]. Mechanical and biological factors are
implicated in disease etiology, while DDD also seems to alter disk cell
mechano-responsiveness [104].
Non-pathological and pathological signaling following mechanical
stimulation in human NP cells seems to differ. More speciﬁcally, non-
pathological mechanotransduction is carried out through integrins
and results in decreased aggrecan expression, an effect not observed
in pathological conditions [105]. These ﬁndings have also been
conﬁrmed by a newstudy that showed that RGD-integrins are implicated
in mechanotransduction following cyclic tensile strain in non-patho-
logical AF cells by phosphorylating FAK, an effect not observed in
pathological IVDs [106,107].Fig. 2.Mechanotransduction aberrations in bone cancer development. Mechanotransduction s
bone pathologies is depicted. FAK, focal adhesion kinase; Src, proto-oncogene tyrosine–protei
tenascin-C; mTOR, mechanistic target of rapamycin; ROCK-I/II, Rho-associated protein kinase-Another study that underlines the different pathways implicated in
pathological and healthy IVD cells demonstrated that while both IL-1
and IL-4 are involved in mechanotransduction after cyclic tensile strain
on AF cells in healthy tissues, that is not the case in degenerative tissues
[108]. Surprisingly, IL-1 levels are found to be elevated with increased
disk degeneration severity, suggesting a role for IL-1 as a diseasemarker
[109].7. Osteoporosis
Osteoporosis, which is estimated to affect more than 200 million
patients worldwide and more than one third of postmenopausal
women [110,111], is characterized by decreased bone mass, bone
matrix degeneration, increased bone fragility and elevated risk of frac-
tures [111]. Its pathology lies in bone remodeling deregulation that can
be attributed to several factors like diet, physical status, hormone levels,
cytokine levels or other underlying diseases [112]. Disuse osteoporosis
is caused by non-weight bearing, immobilization, or long-term bed rest
andaffects an ever increasingnumberof people around theworld. Studies
show that osteoblasts in disuse osteoporosis cannot proceed to normal
level bone synthesis after osteoclast activation, resulting in reduced
overall bone mass [113].
New research focuses on osteocyte network for the study of
mechanisms underpinning disuse osteoporosis. Increased expression of
BCL2 in osteoblasts was found to result in decreased osteocyte process
number as well as increased osteocyte apoptosis levels [114]. For this
reason, researchers used a BCL2 transgenic murine model with non-
functional osteocyte network, in order to identify molecules involved
in disuse osteoporosis and more speciﬁcally in bone loss occurring
after unloading. Pyruvate dehydrogenase kinase 4 (PDK4) expression in
wild-type mice was found to be upregulated after unloading and down-
regulated following reloading, whereas this was not the case in BCL2
transgenic mice. Its increased expression in osteoblasts and boneignaling that has been found altered in osteosarcomas and chondrosarcomas among other
n kinase Src; EGF, pro-epidermal growth factor; IGF-1, insulin-like growth factor I; TN-C,
I/II; MEK-1, dual speciﬁcity mitogen-activated protein kinase kinase 1; Hh, hedgehog.
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osteoclastogenesis. On the other hand, in the BCL transgenic model
absence of PDK4 expression during unloading caused deregulated
osteoclastogenesis. Pdk4−/− animals were characterized by normal
bone development and bone maintenance. At unloading however,
no bone mass decrease was noted as it happens in wild-type mice
through osteoclastogenesis and receptor activator of nuclear factor
kappa-B ligand (RANKL) pathways. Moreover, mice lacking PDK4
expression showed reduced osteoclast differentiation of marrow-
derived monocyte/macrophage lineage cells (BMMs) in the presence
of macrophage colony-stimulating factor (M-CSF) and RANKL [114].
The aforementioned results highlight the role of PDK4 in unloading
conditions and possibly disuse osteoporosis.
Sclerostin, which is encoded by the Sost gene and secreted by adult
bone osteocytes, is a Wnt signaling antagonist in osteoblasts [115–118]
and a potent inhibitor of bone development [119–122]. Mechanical
loading has been shown to decrease sclerostin expression and increase
bone synthesis [123]. During unloading sclerostin levels have been
found to be increased, but some argue that its levels during unloading
are region-speciﬁc [124–126]. Nevertheless, sclerostin expression has
been shown to be regulated by mechanical signals while it has also
been shown to be involved in disuse bone loss [127]. Studies aiming at
elucidating the role of sclerostin undermechanical unloading conditions
have shown that sclerostin is implicated in the process by antagonizing
Wnt/β-catenin signaling. More speciﬁcally, the lack of sclerostin expres-
sion in Sost−/−mice resulted in less bone loss during unloading, unlike
the observations in wild-type animals. Furthermore, in mice lacking
sclerostin expression thedecrease of bone synthesis following unloading
was blocked andWnt/β-catenin signalingwas not affected, as is the case
inwild-type animals [128]. In addition, increased sclerostin serum levels
in humans suffering from bone loss following immobilization were pos-
itively correlated with bone resorption and negatively correlated with
bone synthesis markers [129]. Therefore, sclerostin emerges as a poten-
tial target for disuse osteoporosis. A recent study employed an antibody
against sclerostin, SclAbII, in adult mice with positive results regarding
bone mass quantity. More speciﬁcally, the antibody was able to prevent
disuse-related bone loss and enhance bone synthesis during normal
loading and unloading conditions [130]. Other studies have shown that
simulated resistance training during disuse is able to enhance cortical
bone density and decrease sclerostin levels in rats [131].
Signaling through β-catenin in co-ordination with a group of
GTPases plays a crucial role in bone synthesis however researchers
have demonstrated their role in bone loss as well. More speciﬁcally, it
was shown that β-catenin signaling is essential for regulation of ras
homolog gene family member A (RhoA) GTPase after unloading, and
that RhoA regulates β-catenin signaling responsiveness to unloading
[132].
Beta1 integrins comprise mechanoresponsive molecules that have
been shown to play a role in mechanotransduction during disuse.
Speciﬁcally, beta1 integrins were demonstrated to regulate bone loss
and alterations in cortical bone geometry during disuse [133]. In
addition, alpha5beta1 integrin has been implicated in apoptotic
processes during unloading. More speciﬁcally, according to a recent
study, unloading in rats triggered a decrease in tibial bone mass, early
apoptosis of osteoblasts as well as delayed osteocyte apoptosis. During
unloading, expression levels of alpha5beta1 integrin and phosphorylated
phosphatidyl-inositol-3 kinase (p-PI3K) were found decreased. Further-
more, the p-PI3K reduction was correlated with decreased Bcl-2 survival
protein levels [134].
Osteoporosis is mostly an age-related disease. Several
mechanotransduction pathways have been found altered in models
investigatingmature and aged animals. For example, itwas demonstrated
that there was a decrease in mineralization levels as well as a delay in
calciﬁcation in aged rats. Furthermore, differentiating mesenchymal
stem cells (MSCs) of aged animalswere characterized by reduced respon-
siveness to short and long periods of mechanical cues through ERK1/2signaling as well as to long periods of mechanical loading through NO
pathways. In addition, a greater increase was observed in PGE2 signaling
levels in MSCs from aged animals, most likely as a compensation for
decreased ERK1/2 and NO signaling [135]. Moreover, other groups have
demonstrated reduced calcium signaling in osteoblasts of aged animals
following application of oscillatory ﬂuid shear stress [136], while others
have shown decreased calcium inﬂux in osteoblasts following ﬂuid ﬂow
stimulus with ascending age [137]. Additionally, a decreased stimulation
of osteoprogenitor formation by IGF-1 was demonstrated in aged osteo-
blasts [138]. Slightly elevated levels of NO, PGE2 and cytochrome c oxidase
subunit 2 (COX-2) mRNA were observed in osteoblasts of aged patients
with osteoporosis after pulsatileﬂuidﬂowapplication [136,139], whereas
other studies have not detected age-dependent relative increase in COX-2
and c-fos expression levels following ﬂuid ﬂow mechanical stimulus
application in murine models [140].
Reduced estrogen levels are known to play a key role in age-related
bone mass decrease and osteoporosis. Recently, researchers have
shown the combined effects of estrogen receptor related pathways
and mechanotransduction signaling on bone loss. More speciﬁcally, an
interaction between estrogen receptor and Wnt/β-catenin pathways
has been observed. Following mechanical stimulation, estrogen receptor
signaling in co-ordination with mechanical signaling results in increased
expression of PGE2, which, in turn, leads to decreased sclerostin produc-
tion. As sclerostin is an endogenousWnt signaling antagonist and a bone
synthesis inhibitor, the above signals result in augmented bone formation
[141]. When these signals are not present, as in age-related osteoporosis,
reduced bone matrix synthesis is observed. Because of its properties, a
decrease in sclerostin in combination with exercise has been proposed
as a therapeutic strategy against bone loss at greater ages [128] (Fig. 3).
8. Conclusions — outlook
Bone remodeling comprises a process of great signiﬁcance for the
maintenance of bone health, while its alterations advance bone disease
development. Bone remodeling is largely affected by mechanical
signals, signals that travel towards the nucleus in order to modulate
speciﬁc gene responses [142–146]. This process, which is called
mechanotransduction, embraces oneof the cornerstones of bonebiology
and pathobiology. In order to better understand bone (patho)physiol-
ogies, we need to further investigate the molecular pathways underpin-
ning bone remodeling and mechanotransduction in health and disease.
The acquired information will not only elucidate molecular mechanisms
implicated in bone disorders but will also result in plotting novel thera-
peutic strategies that will obviate the negative side-effects [147] and
identify reliable diagnostic or prognostic disease markers. Researchers,
based on current knowledge, have begun testing mechanostimulation
systems alone or in combination with pharmacological agents, in order
to ameliorate bone disease effects. Elucidation of themolecular cascades
and cross-talks following mechanical stimulation under physiological
and pathological conditionswould further enable tomake a step forward
towards successful treatments. Mechanostimulation seems to be the
future in treating bonemaladies caused by abnormalmechanical signals.
Clariﬁcation of the molecular signaling events involved in these patho-
logical situations will facilitate the development of reliable prognostic/
diagnostic tools as well as treatment strategies for a variety of bone
diseases.
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Fig. 3. Altered mechanotransduction in age-related osteoporosis. Alterations in mechanotransduction pathways have different effects for each cell type. Signaling pathways affected following
changed mechanotransduction in mesenchymal stem cells (MSCs) are depicted on the left while pathways affected in osteoblasts on the right. Osteoporosis comprises the end result of
mechanotransduction deregulations. MSCs, mesenchymal stem cells; ERK1/2, extracellular-regulated kinase 1/2; NO, nitric oxide; RANKL, receptor activator of nuclear factor kappa-B ligand;
PGE2, prostaglandin E2; IGF-1, insulin-like growth factor I; COX-2, cytochrome c oxidase.
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